Gisela Mezquida1, Bibiana Cabrera2, Miquel Bioque2, Silvia Amoretti2, Antonio Lobo3, Ana González-Pinto4, Ana Espliego5, Iluminada Corripio6, Eduard Vieta7, Josefina Castro-Fornieles8, Daniel Bergé9, Maria J Escartí10, Ángela Ibañez11, Rafael Penadés12, Ana M Sánchez-Torres13, Miguel Bernardo14. 1. Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clínic de Neurociències (ICN), Hospital Clínic de Barcelona, Spain. 2. Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clínic de Neurociències (ICN), Hospital Clínic de Barcelona, Spain; Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain. 3. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), University of Zaragoza, Spain. 4. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Araba University Hospital, Bioaraba Research Institute, Spain; University of the Basque Country (UPV-EHU), Spain. 5. Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Madrid, Spain. 6. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Department of Psychiatry, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 7. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Psychiatry and Psychology, Clinical Institute for the Neurosciences (ICN), Hospital Clinic of Barcelona, Spain; Department of Medicine, University of Barcelona, Spain. 8. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medicine, University of Barcelona, Spain; Department of Child and Adolescent Psychiatry and Psychology, Hospital Clinic of Barcelona, Spain. 9. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Hospital del Mar Medical Research Institute (IMIM) - UAB, Neurosciences, Psychiatry, Barcelona, Spain. 10. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Department of Psychiatry, Valencia Clinic Hospital, Valencia, Spain. 11. Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Department of Psychiatry, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain. 12. Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clínic de Neurociències (ICN), Hospital Clínic de Barcelona, Spain; Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medicine, University of Barcelona, Spain. 13. Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. 14. Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clínic de Neurociències (ICN), Hospital Clínic de Barcelona, Spain; Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medicine, University of Barcelona, Spain. Electronic address: bernardo@clinic.ub.es.
Abstract
AIMS: This study aimed to investigate the course of negative symptoms and its stability over a two-year period following a first-episode schizophrenia (FES) and the possible predictors of higher severity in this symptomatology after this period. METHODS: In this longitudinal two-year prospective follow-up study we included 268 patients with a FES, according to DSM-IV. Analysis of variance was conducted in patients who completed the full follow-up to study changes in negative symptoms over three visits. Regression analyses were conducted to show correlates and potential predictors of negative symptoms at two-year follow-up. RESULTS: There was a significant effect for time in negative symptomatology, which was less severe at one-year follow-up after a FES and remained stable up to two years (Time 1>Time 2>Time 3); F(2,151)=20.45, p<0.001. Poorer premorbid adjustment (p=0.01) and higher negative symptoms at baseline (p<0.001) made a significant contribution to the changes in the negative symptoms severity at two-years after a FES (R2=0.21, p<0.001). CONCLUSIONS: We found a reduction in the negative symptomatology at one-year after a FES. This change remained stable at two-year. Our results suggested that the presence of this symptomatology early in the course of the illness, together with a poorer premorbid adjustment, predict more severe negative symptoms at mid-term outcome.
AIMS: This study aimed to investigate the course of negative symptoms and its stability over a two-year period following a first-episode schizophrenia (FES) and the possible predictors of higher severity in this symptomatology after this period. METHODS: In this longitudinal two-year prospective follow-up study we included 268 patients with a FES, according to DSM-IV. Analysis of variance was conducted in patients who completed the full follow-up to study changes in negative symptoms over three visits. Regression analyses were conducted to show correlates and potential predictors of negative symptoms at two-year follow-up. RESULTS: There was a significant effect for time in negative symptomatology, which was less severe at one-year follow-up after a FES and remained stable up to two years (Time 1>Time 2>Time 3); F(2,151)=20.45, p<0.001. Poorer premorbid adjustment (p=0.01) and higher negative symptoms at baseline (p<0.001) made a significant contribution to the changes in the negative symptoms severity at two-years after a FES (R2=0.21, p<0.001). CONCLUSIONS: We found a reduction in the negative symptomatology at one-year after a FES. This change remained stable at two-year. Our results suggested that the presence of this symptomatology early in the course of the illness, together with a poorer premorbid adjustment, predict more severe negative symptoms at mid-term outcome.
Authors: Wing Chung Chang; Ryan Wui Hang Ho; Jennifer Yee Man Tang; Corine Sau Man Wong; Christy Lai Ming Hui; Sherry K W Chan; Edwin M H Lee; Yi Nam Suen; Eric Y H Chen Journal: Schizophr Bull Date: 2019-04-25 Impact factor: 9.306
Authors: Wing Chung Chang; Jasmine Tsz Ting Liu; Christy Lai Ming Hui; Sherry Kit Wa Chan; Edwin Ho Ming Lee; Yi Nam Suen; Eric Yu Hai Chen Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-06-22 Impact factor: 5.270
Authors: Joseph Ventura; Kenneth L Subotnik; Denise Gretchen-Doorly; Laurie Casaus; Michael Boucher; Alice Medalia; Morris D Bell; Gerhard S Hellemann; Keith H Nuechterlein Journal: Schizophr Res Date: 2017-11-09 Impact factor: 4.662
Authors: Richard Newton; Alice Rouleau; Anna-Greta Nylander; Jean-Yves Loze; Henrike K Resemann; Sara Steeves; Benedicto Crespo-Facorro Journal: NPJ Schizophr Date: 2018-10-15
Authors: Bill Deakin; John Suckling; Thomas R E Barnes; Kelly Byrne; Imran B Chaudhry; Paola Dazzan; Richard J Drake; Annalisa Giordano; Nusrat Husain; Peter B Jones; Eileen Joyce; Emma Knox; Carl Krynicki; Stephen M Lawrie; Shôn Lewis; Danuta M Lisiecka-Ford; Naghmeh Nikkheslat; Carmine M Pariante; Richard Smallman; Andrew Watson; Steven C R Williams; Rachel Upthegrove; Graham Dunn Journal: Lancet Psychiatry Date: 2018-10-12 Impact factor: 77.056
Authors: Daniela Rodrigues-Amorim; Tania Rivera-Baltanás; María Del Carmen Vallejo-Curto; Cynthia Rodriguez-Jamardo; Elena de Las Heras; Carolina Barreiro-Villar; María Blanco-Formoso; Patricia Fernández-Palleiro; María Álvarez-Ariza; Marta López; Alejandro García-Caballero; José Manuel Olivares; Carlos Spuch Journal: Front Psychiatry Date: 2019-11-29 Impact factor: 4.157
Authors: Juan F Rodríguez-Testal; Salvador Perona-Garcelán; Sonia Dollfus; María Valdés-Díaz; Jesús García-Martínez; Miguel Ruíz-Veguilla; Cristina Senín-Calderón Journal: BMC Psychiatry Date: 2019-10-29 Impact factor: 3.630